Volume 20, Number 9—September 2014
CME ACTIVITY - Research
Pneumocystis jirovecii Pneumonia in Patients with or without AIDS, France
Table 3
Variable | Odds ratio (95% CI) |
---|---|
HIV infection | 0.33 (0.12–0.92) |
Solid organ transplant | 0.08 (0.02–0.31) |
Age, per additional year | 1.04 (1.02–1.06) |
Allogeneic HSCT | 8.6 (1.40–53.02) |
Need for immediate oxygen therapy | 4.06 (1.44–11.5) |
Need for intubation and mechanical ventilation | 16.70 (7.25–38.47) |
Time to PCP treatment, per additional day | 1.11 (1.04–1.18) |
*Variables from Tables 1 and 2 were introduced into the multivariate model based on their association with hospital mortality by bivariate analysis with p values <0.20. Higher numbers indicate increased odds, with 1 as the cutoff point (i.e., values <1.00 indicate decreased risk, >1.00 increased risk). Goodness of fit (Hosmer-Lemeshow test) was 0.61. PCP, Pneumocystis jirovecii pneumonia; HSCT, hematopoietic stem cell transplant.
1Deceased.
Page created: August 14, 2014
Page updated: August 14, 2014
Page reviewed: August 14, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.